Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.37 |
| ▸ | MAOB | P27338 | 6/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL709575 | 0.94 | SYK (0.34) | FFAR1SYKNOS1 | |
| SCHEMBL10206666 | 0.93 | MAOB (0.39) | FAAHFFAR1MAOBMAOA | |
| Trifluoroacetic Acid SCHEMBL712920 | 0.91 | KDM4E (0.38) | FFAR1NOS1 | |
| Trifluoroacetic Acid SCHEMBL711504 | 0.89 | NOS1 (0.35) | FFAR1SYKNOS1 | |
| Trifluoroacetic Acid SCHEMBL708256 | 0.89 | GUCY1B2 (0.36) | SYK | |
| Trifluoroacetic Acid SCHEMBL709074 | 0.89 | NAMPT (0.36) | ALOX5APSYKNOS1 | |
| Trifluoroacetic Acid SCHEMBL718789 | 0.88 | PDE4A (0.35) | FFAR1ALOX5SYK | |
| Trifluoroacetic Acid SCHEMBL713293 | 0.88 | MEN1 (0.36) | FFAR1 | |
| Trifluoroacetic Acid SCHEMBL711889 | 0.88 | HDAC3 (0.34) | MAOBSYK | |
| Trifluoroacetic Acid SCHEMBL711518 | 0.86 | PDE4A (0.36) | FFAR1ALOX5APNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | FAAH 3981/4885FFAR1 3394/4885MAOB 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.